1,4-Phenylenebis(methylene)selenocyanate, but not selenomethionine, inhibits androgen receptor and Akt signaling in human prostate cancer cells

Cancer Prevention Research

Volumn 3, Issue 8, 2010, Pages 975-984

  Facompre, Nicole D ^a   El Bayoumy, Karam ^a   Sun, Yuan Wan ^a   Pinto, John T ^b   Sinha, Raghu ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 PHENYLENEBIS(METHYLENE)SELENOCYANATE; ANDROGEN RECEPTOR; ANTIANDROGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SELENOMETHIONINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SPECIFICITY; HORMONE RESISTANCE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; MODELS, BIOLOGICAL; ONCOGENE PROTEIN V-AKT; ORGANOSELENIUM COMPOUNDS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SELENOMETHIONINE; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 77955438911     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0054     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Facompre N, El-Bayoumy K. Potential stages for prostate cancer prevention with selenium: implications for cancer survivors. Cancer Res 2009;69:2699-703.
3. Clark LC, Combs GF, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA 1996;276:1957-63.
4. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers. JAMA 2009;309:39-51.
5. El-Bayoumy K. The negative results of the SELECT study do not necessarily discredit the selenium-cancer hypothesis. Nutr Cancer 2009;61:285-6.
6. Chan JM, Oh WK, Xie W, et al. Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. J Clin Oncol 2009;27:3577-83.
7. Lee JI, Nian H, Cooper AJL, et al. α-Keto acid metabolites of naturally-occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells. Cancer Prev Res 2009;2:683-93.
8. Zhao H, Domann FE, Zhong W. Apoptosis induced by selenomethionine and methioninase is superoxide mediated and p53 dependent in human prostate cancer cells. Mol Cancer Ther 2006;5: 3275-84.
9. Zhao H, Brooks HD. Selenomethionine induced transcription programs in human prostate cancer cells. J Urol 2007;177:743-50.
10. Pinto JT, Sinha R, Papp K, Facompre ND, Desai D, El-Bayoumy K. Differential effects of naturally occurring and synthetic organoselenium compounds on biomarkers in androgen responsive and androgen independent human prostate carcinoma cells. Int J Cancer 2007;120:1410-7.
11. Sinha R, Pinto JT, Facompre N, Kilheffer J, Baatz JE, El-Bayoumy K. Effects of naturally occurring and synthetic organoselenium compounds on protein profiling in androgen responsive and androgen independent human prostate cancer cells. Nutr Cancer 2008;60:267-75.
12. Corcoran NM, Najdovska M, Costello AJ. Inorganic selenium retards progression of experimental hormone refractory prostate cancer. J Urol 2004;171:907-10.
13. Li GX, Lee HJ, Wang Z, et al. Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. Carcinogenesis 2008;29:1005-12.
14. McCormick DL, Rao KVN, Johnson WD, Bosland MC, Lubet RA, Steele VE. Null activity of selenium and vitamin E as cancer chemopreventive agents in the rat prostate. Cancer Prev Res 2010;3:381-92.
15. Reddy BS, Wynn TT, El-Bayoumy K, Upadhyaya P, Fiala E, Rao CV. Evaluation of organoselenium compounds for potential chemopreventive properties in colon cancer. Anticancer Res 1996;16: 1123-7.
16. Prokopczyk B, Amin S, Desai DH, Kurtzke C, Upadhyaya P, El-Bayoumy K. Effects of 1,4-phenylenebis(methylene)selenocyanate and selenomethionine on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced tumorigenesis in A/J mouse lung. Carcinogenesis 1997;18:1855-67.
17. Das A, Desai D, Pittman B, Amin S, El-Bayoumy K. Comparison of the chemopreventive efficacies of 1,4-phenylenebis(methylene)selenocyanate and selenium-enriched yeast on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mouse. Nutr Cancer 2003;46:179-85.
18. El-Bayoumy K, Sinha R. Mechanisms of mammary cancer chemoprevention by organoselenium compounds. Mutat Res 2004;551:181-97.
19. Cho SD, Jiang C, Malewicz B, et al. Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription. Mol Cancer Ther 2004;3:605-11.
20. Dong Y, Lee SO, Zhang H, Marshall J, Gao AC, Ip C. Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res 2004;64:19-22.
21. Chun JY, Nadiminty N, Lee SO, Onate SA, Lou W, Gao AC. Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer. Mol Cancer Ther 2006;5:913-8.
22. Husbeck B, Bhattacharyya RS, Feldman D, Knox SJ. Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action. Mol Cancer Ther 2006;5:2078-85.
23. Hu H, Jiang C, Li G, Lu J. PKB/AKT and ERK regulation of caspase-mediated apoptosis by methylseleninic acid in LNCaP prostate cancer cells. Carcinogenesis 2005;26:1374-81.
24. Wu Y, Zu K, Warren MA, Wallace PK, Ip C. Delineating the mechanism by which selenium deactivates Akt in prostate cancer cells. Mol Cancer Ther 2006;5:246-52.
25. Lee SO, Chun JY, Nadiminty N, et al. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate 2006;66:1070-5.
26. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
27. Edwards J, Bartlett JM. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor. BJU Int 2005;95: 1320-6.
28. Malik SN, Brattain M, Ghosh PM, et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002;8:1168-71.
29. Kreisberg JI, Malik SN, Prihoda TJ, et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004;64:5232-6.
30. El-Bayoumy K, Chae YH, Upadhyaya P, Meschter C, Cohen LA, Reddy BS. Inhibition of 7,12-dimethylbenz(a)anthracene-induced tumors and DNA adduct formation in the mammary glands of female Sprague-Dawley rats by the synthetic organoselenium compound 1,4-phenylenebis(methylene)selenocyanate. Cancer Res 1992;52: 2402-7.
31. Dong Y, Zhang H, Gao AC, Marshall JR, Ip C. Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancerspecific biomarkers. Mol Cancer Ther 2005;4:1047-55.
32. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376:37-43.
33. Tewari M, Quan LT, O'Rourke K, et al. Yama/CPP32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995;81:801-9.
34. Lin HK, Yeh S, Kang HY, Chang C. Akt suppresses androgeninduced apoptosis by phosphorylating and inhibiting androgen receptor. PNAS 2001;98:7200-5.
35. Sinha R, El-Bayoumy K. Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds. Curr Cancer Drug Targets 2004;4:13-28.
36. Lin HK, Hu YC, Yang L, et al. Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/ Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem 2003;278:50902-7.
37. Chen KM, Spratt TE, Stanley BA, et al. Inhibition of nuclear factor-κB DNA binding by organoselenocyanates through covalent modification of the p50 subunit. Cancer Res 2007;67:10475-83.
38. Blessing H, Kraus S, Heindl P, Bal W, Hartwig A. Interaction of selenium compounds with zinc finger proteins involved in DNA repair. Eur J Biochem 2004;271:3190-9.
39. Menter DG, Sabichi AL, Lippman SM. Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 2000;9: 1171-82.